Summary
A previously performedpost-mortem study comparing monoaminergic indices in the brains of 14 schizophrenic patients and 10 patients with psychosis not diagnosed as schizophrenia, with age-matched control cases without any known neuropsychiatric illness, was re-investigated, using multivariate analysis. The monoaminergic patterns showing up in this analysis suggested the existence of at least two different forms of the disease, both of which could be distinguished from the controls as well as from each other. One of the schizophrenic groups consisted of paranoid cases, and had a relatively mild family history, whereas the other group, mainly consisting of hebephrenic cases, had a severe family history. The former group showed low levels of dopamine and high levels of serotonergic precursor and metabolite, whereas the latter group in some respects tended to show the opposite aberrations. Neuroleptic treatment did not seem to account for the different biochemical profiles, unless one assumes that this treatment can cause completely different monoaminergic aberrations in different individuals. Instead, one could argue that the different biochemical profiles found are characteristic of the disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atack CV, Magnusson T (1978) A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using column of strongly acidic cation exchange resin. Acta Pharmacol Toxicol 42: 35–57
Beskow J, Gottfries CG, Roos BE, Winblad B (1976) Determination of monoamine and monoamine metabolites in the human brain: post-mortem studies in a group of suicides and in a control group. Acta Psychiatr Scand 53: 7–20
Carlsson A, Lindqvist M, Kehr W (1974) Postmortal accumulation of 3-MT in brain. Naunyn Schmiedebergs Arch Pharmacol 284: 365–372
Carlsson A, Svennerholm L, Winblad B (1980) Seasonal and circadian monoamine variations in human brains examinedpost mortem. Acta Psychiatr Scand 61: 75–83
Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease. TINS 13: 272–276
Clark M, Cramer RDIII (1993) The probability of chance correlation using partial least squares (PLS). Quant Struct-Act Relat 12: 137–145
Costall B, Naylor RJ (1986) Neurotransmitter hypothesis of schizophrenia. In: Bradley PB, Hirsch SR (eds) The psychopharmacology and treatment of schizophrenia. Oxford University Press, London, pp 132–165
Dunn WJIII, Wold S (1990) Pattern recognition techniques in drug design. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry, vol 4. Pergamon Press, London, pp 691–714
Farley IJ, Price KS, McCullough E, Deck JHN, Hordynski W, Hornykiewicz O (1978) Norepinephrine in chronic paranoid schizophrenia. Science 200: 456–457
Gattaz WF, Gasser T, Beckmann H (1985) Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry 20: 360–366
Gottfries CG, Adolfsson R, Winblad B (1981) Analytical problems in post-mortem brain studies. 12th CINP Congress, Göteborg, p 47
Gottfries CG, Roos BE, Winblad B (1974) Determination of 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and homovanillic acid in brain tissue from an autopsy material. Acta Psychiatr Scand 50: 406–507
Jackson JE (1991) A user's guide to principal components. Wiley, New York Chichester Brisbane Toronto Singapore, pp 1–563
Jellum E, Björnsson I, Nesbakken R, Johansson E, Wold S (1981) Classification of human cancer cells by means of capillary gas chromatography and pattern recognition analysis. J Chromatogr 217: 231–237
Kay SR (1991) Pyramidical model of schizophrenia. In: van Praag HM (ed) Positive and negative syndromes in schizophrenia: assessment and research. Brunner/Mazel, New York, pp 181–193
Kendell RE (1975) What are our criteria for a diagnosis of schizophrenia? In: van Praag HM (ed) On the origin of schizophrenic psychoses. De Erven Bohn BV, Amsterdam, pp 125–137
Kim JS, Kornhuber HH, Kornhuber J, Kornhuber ME (1985) Glutamic acid and the dopamine hypothesis of schizophrenia. In: Shagass C (ed) Biological psychiatry. Elsevier, Amsterdam New York, pp 1109–1111
Kleinman JE (1986) Postmortem neurochemistry studies in schizophrenia. In: Nasrallah HA, Weinberger DR (eds) Handbook of schizophrenia. Elsevier, Amsterdam, pp 349–360
Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Zur biochemischen Theorie der Schizophrenie. Nervenarzt 55: 602–606
Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H (1989) [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231–236
Lieberman JA, Koreen AR (1993) Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 19: 371–429
Nordström A-L (1993) PET evaluation of dopamine hypothesis for antipsychotic drugs and schizophrenia. Thesis, Karolinska Institute Stockholm
Seeman P, Guan H-C, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441–445
Sjöström M, Wold S, Söderström B (1984) PLS discriminant plots. In: Elsemaa GS, Kanal LN (eds) Pattern recognition in practice II. Elsevier, Amsterdam, pp 461–470
Stone M (1974) Cross validatory choice and assessment of statistical predictions. J Roy Stat Soc B 36: 111–147
Toru M, Watanabe S, Shibuyia H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78: 121–137
Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm [GenSect] 94: 11–19
Wiesel F-A, Blomqvist G, Venizelos N, Bjerkenstedt L, Halldin C, Hagenfelt L, Sjögren I (1991) Altered transport of tyrosine across the blood-brain barrier in patients with schizophrenia. Biol Psychiatry 2: 337–340
Winblad B, Bucht G, Gottfries CG, Roos B-E (1979) Monoamines and monoamine metabolites in brains from demented shizophrenics. Acta Psychiatr Scand 60: 17–28
Wold H (1975) Soft modelling by latent variables; the non-linear iterative partial least squares approach. In: Gani J (ed) Perspectives in probability and statistics. Papers in Honor of M.S. Bartlett. Academic Press, London
Wold S (1978) Cross-validatory estimation of the number of components in factor and principal component models. Technomertrics 20: 397–405
Wold S, Albano C, Dunn WJ III, Edlund U, Esbensen K, Geladi P, Hellberg S, Johansson E, Lindberg W, Sjöström M (1984) Multivariate data analysis in chemistry. NATO Adv Study in Chemometrics, Cosenza, pp 17–95
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hansson, L.O., Waters, N., Winblad, B. et al. Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J. Neural Transmission 98, 217–235 (1994). https://doi.org/10.1007/BF01276538
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01276538